Vitamin A Supplementation at Birth Alters Vaccine Immune Responses Without Improving Antibody Levels in Infants
This randomized, placebo-controlled intervention trial evaluated the impact of neonatal Vitamin A supplementation on vaccine responses. The study enrolled 306 infants in Dhaka, Bangladesh. Participants received 50,000 IU Vitamin A given within 48 h of birth or placebo. Follow-up assessments occurred at 6 w, 15 w and 2 y.
Primary outcomes included response to Bacillus Calmette Guérin, oral polio virus, Tetanus Toxoid and Hepatitis B virus vaccines. Antibody responses to vaccines showed no effect. Secondary outcomes assessed delayed-type hypersensitivity at 15 w for BCG. DTH response to BCG increased in infants above the birthweight median. CD4 T-cell stimulation index for BCG and SEB were reduced. TT- and HBV-specific IL-2 and IL-5 increased. SEB-stimulated IL-5 increased in girls but decreased in boys. BCG-specific IL-13 increased in girls. TT-specific and SEB-stimulated IL-17 decreased in boys. IL-10 in response to BCG, HBV below birthweight median only and SEB decreased. T-cell proliferation and cytokine production were measured at 6 w, 15 w and 2 y.
Safety data regarding adverse events, serious adverse events, discontinuations and tolerability were not reported. Limitations and practice relevance were not reported. The mixed immune findings suggest complex interactions without clear clinical benefit. Further research is needed to determine utility. Clinicians should note the lack of safety information when considering this intervention.